Updates are available Correction dated 2025-10-17
Click to view Correction: https://doi.org/10.1038/s41375-025-02788-z
-
Authors
Vu, Thi Thanh
Stölzel, Friedrich
Wang, Kristy W.
Röllig, Christoph
Tursky, Melinda L. https://orcid.org/0000-0001-7777-4491
Molloy, Timothy J. https://orcid.org/0000-0003-0927-3382
Ma, David D.
-
Funding
Funding for this research was provided by:
DFG grant "Collaborative Research Center 655", Dresden, Project B7
- License Information
-
More Information
Article History
Received: 6 May 2020
Revised: 12 October 2020
Accepted: 10 November 2020
First Online: 1 December 2020
Change Date: 20 October 2025
Change Type: Update
Change Details: The original online version of this article was revised: Following the publication of this article, an overlap was noted in two of the histological images in Figure 8b, labelled “Nutlin-3a + Cytarabine”. The tissue samples used are now >7 years old and unfortunately are unable to be located. As this figure is an ancillary figure, that does not alter the key findings of the paper, the decision was taken to remove the figure and legend. The sentence referring to this figure in the final paragraph of the Results section has also been removed: “Improved survival was consistent with significantly lower human CD45 positive (hCD45+) leukemic cell infiltrate in the spleen of miR-10a inhibited vs control animals collected after 7 days of treatment (all except vehicle p < 0.05; Fig. 8b). The original article has been corrected.
Change Date: 17 October 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41375-025-02788-z
Compliance with ethical standards
:
: TJM and DDM are named inventors on a patent application arising from the work described.
